KEY POINTS
  • GlaxoSmithKline's dividend could be at risk of being slashed at an investor meeting Wednesday morning as the company looks to invest in its growth.
  • "If the rumors are true and GlaxoSmithKline really takes a meat-ax to its dividend, then I think you need to be prepared for the stock to get slammed as income-oriented investors dump it," CNBC's Jim Cramer said.
  • "But after it sells off, you could get a good buying opportunity," the "Mad Money" host said.

In this article

CNBC's Jim Cramer gave investors a primer on what to watch for when pharmaceutical giant GlaxoSmithKline holds an investor day Wednesday morning.

The British-based company currently pays out a 5.56% dividend to shareholders as CEO Emma Walmsley leads a reshuffling in the business.

In this article